ابيضاض الدم الليمفاوي الحاد: ماذا يُفعل عندما لا يحقق العلاج الكيميائي الاستقرائي هدأةً كاملة

References

• For patients who are MRD-positive, blinatumomab (Blincyto®) is often the recommended treatment.
• Blinatumomab is a liquid administered slowly into a vein by IV as a continuous infusion over a period of 28 days for each cycle.
• For most patients who are MRD-negative, consolidation consists of multiagent chemotherapy.
• Consolidation is usually given in cycles over 4 to 6 months.
• As part of consolidation, some patients in remission may receive a stem cell transplant.
• Doctors usually recommend stem cell transplantation for patients who are likely to relapse due to high-risk genetic features, or for patients who have high rates of MRD after induction.